Literature DB >> 19222366

Transient in vivo beta-globin production after lentiviral gene transfer to hematopoietic stem cells in the nonhuman primate.

Jun Hayakawa1, Takahiro Ueda, Leszek Lisowski, Matthew M Hsieh, Kareem Washington, Oswald Phang, Mark Metzger, Allen Krouse, Robert E Donahue, Michel Sadelain, John F Tisdale.   

Abstract

Inherited disorders of globin synthesis remain desirable targets for hematopoietic stem cell (HSC)-based therapies. Gene transfer using retroviral vectors offers an alternative to allogeneic HSC transplantation by the permanent integration of potentially therapeutic genes into primary autologous HSCs. Although proof of principle has been demonstrated in humans, this approach has been met by formidable obstacles, and large-animal models have become increasingly important for the preclinical development of gene addition strategies. Here we report lentiviral gene transfer of the human beta-globin gene under the control of the globin promoter and large fragments of the globin locus control region (LCR) in the nonhuman primate. Using an HIV-1, vesicular stomatitis virus glycoprotein G (VSV-G)-pseudotyped vector, modified to overcome a species-specific restriction to HIV-1, gene transfer to colony-forming units (CFU) derived from mobilized peripheral blood (PB) rhesus CD34+ cells was 84.4 +/- 2.33%. Erythroid cells derived from transduced rhesus CD34+ cells expressed human beta-globin at high levels as assessed by flow cytometry with a human beta-globin-specific antibody. Two rhesus macaques (RQ3586 and RQ3583) were transplanted with mobilized PB CD34+ cells transduced with our modified HIV vector at a multiplicity of infection of 80. High gene transfer rates to CFUs were achieved in vitro (RQ3586, 87.5%; RQ3583, 83.3%), with efficient human beta-globin expression among erythroid progeny generated in vitro. Early posttransplantation, gene transfer rates of 5% or higher were detectable and confirmed by genomic Southern blotting, with equivalent-level human beta-globin expression detected by flow cytometry. Long-term gene marking levels among mononuclear cells and granulocytes assessed by quantitative polymerase chain reaction gradually decreased to about 0.001% at 2 years, likely due to additional HIV-1 restrictive elements in the rhesus macaque. No evidence of clonal hematopoiesis has occurred in our animals in up to 2 years. Current efforts are aimed at developing a lentiviral vector capable of efficiently transducing both human and rhesus HSCs to allow preclinical modeling of globin gene transfer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19222366      PMCID: PMC2828625          DOI: 10.1089/hum.2008.186

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  55 in total

Review 1.  Gene therapy for the hemoglobin disorders: past, present, and future.

Authors:  D A Persons; A W Nienhuis
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

2.  Many multipotential gene-marked progenitor or stem cell clones contribute to hematopoiesis in nonhuman primates.

Authors:  H J Kim; J F Tisdale; T Wu; M Takatoku; S E Sellers; P Zickler; M E Metzger; B A Agricola; J D Malley; I Kato; R E Donahue; K E Brown; C E Dunbar
Journal:  Blood       Date:  2000-07-01       Impact factor: 22.113

3.  Systematic determination of the packaging limit of lentiviral vectors.

Authors:  M Kumar; B Keller; N Makalou; R E Sutton
Journal:  Hum Gene Ther       Date:  2001-10-10       Impact factor: 5.695

4.  Prolonged high-level detection of retrovirally marked hematopoietic cells in nonhuman primates after transduction of CD34+ progenitors using clinically feasible methods.

Authors:  T Wu; H J Kim; S E Sellers; K E Meade; B A Agricola; M E Metzger; I Kato; R E Donahue; C E Dunbar; J F Tisdale
Journal:  Mol Ther       Date:  2000-03       Impact factor: 11.454

5.  Marking and gene expression by a lentivirus vector in transplanted human and nonhuman primate CD34(+) cells.

Authors:  D S An; R P Wersto; B A Agricola; M E Metzger; S Lu; R G Amado; I S Chen; R E Donahue
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

6.  Persistent low-level engraftment of rhesus peripheral blood progenitor cells transduced with the fanconi anemia C gene after conditioning with low-dose irradiation.

Authors:  E M Kang; Y Hanazano; P Frare; E F Vanin; M De Witte; M Metzger; J M Liu; J F Tisdale
Journal:  Mol Ther       Date:  2001-06       Impact factor: 11.454

7.  Preselection of retrovirally transduced bone marrow avoids subsequent stem cell gene silencing and age-dependent extinction of expression of human beta-globin in engrafted mice.

Authors:  C P Kalberer; R Pawliuk; S Imren; T Bachelot; K J Takekoshi; M Fabry; C J Eaves; I M London; R K Humphries; P Leboulch
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

8.  Lentivirus vector-mediated hematopoietic stem cell gene transfer of common gamma-chain cytokine receptor in rhesus macaques.

Authors:  D S An; S K Kung; A Bonifacino; R P Wersto; M E Metzger; B A Agricola; S H Mao; I S Chen; R E Donahue
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

9.  Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin.

Authors:  C May; S Rivella; J Callegari; G Heller; K M Gaensler; L Luzzatto; M Sadelain
Journal:  Nature       Date:  2000-07-06       Impact factor: 49.962

10.  A correlation of erythrokinetics, ineffective erythropoiesis, and erythroid precursor apoptosis in thai patients with thalassemia.

Authors:  P Pootrakul; P Sirankapracha; S Hemsorach; W Moungsub; R Kumbunlue; A Piangitjagum; P Wasi; L Ma; S L Schrier
Journal:  Blood       Date:  2000-10-01       Impact factor: 22.113

View more
  7 in total

Review 1.  Hematopoietic stem cell gene therapy:assessing the relevance of preclinical models.

Authors:  Andre Larochelle; Cynthia E Dunbar
Journal:  Semin Hematol       Date:  2013-04       Impact factor: 3.851

Review 2.  Gene therapy for sickle cell disease: An update.

Authors:  Selami Demirci; Naoya Uchida; John F Tisdale
Journal:  Cytotherapy       Date:  2018-05-30       Impact factor: 5.414

Review 3.  Contributions of gene marking to cell and gene therapies.

Authors:  Cecilia N Barese; Cynthia E Dunbar
Journal:  Hum Gene Ther       Date:  2011-05-05       Impact factor: 5.695

4.  Stem cell factor-displaying simian immunodeficiency viral vectors together with a low conditioning regimen allow for long-term engraftment of gene-marked autologous hematopoietic stem cells in macaques.

Authors:  Els Verhoeyen; Francis Relouzat; Marie Cambot; Caroline Costa; Didier Nègre; Faézeh Legrand; Christophe Joubert; Roger Le Grand; François-Loïc Cosset; Philippe Leboulch; Anne Dubart-Kupperschmitt; Stephane Prost
Journal:  Hum Gene Ther       Date:  2012-07-11       Impact factor: 5.695

5.  Development of a human immunodeficiency virus type 1-based lentiviral vector that allows efficient transduction of both human and rhesus blood cells.

Authors:  Naoya Uchida; Kareem N Washington; Jun Hayakawa; Matthew M Hsieh; Aylin C Bonifacino; Allen E Krouse; Mark E Metzger; Robert E Donahue; John F Tisdale
Journal:  J Virol       Date:  2009-07-22       Impact factor: 5.103

6.  Endothelial Cells Promote Expansion of Long-Term Engrafting Marrow Hematopoietic Stem and Progenitor Cells in Primates.

Authors:  Jennifer L Gori; Jason M Butler; Balvir Kunar; Michael G Poulos; Michael Ginsberg; Daniel J Nolan; Zachary K Norgaard; Jennifer E Adair; Shahin Rafii; Hans-Peter Kiem
Journal:  Stem Cells Transl Med       Date:  2016-10-14       Impact factor: 6.940

7.  Development of a forward-oriented therapeutic lentiviral vector for hemoglobin disorders.

Authors:  Naoya Uchida; Matthew M Hsieh; Lydia Raines; Juan J Haro-Mora; Selami Demirci; Aylin C Bonifacino; Allen E Krouse; Mark E Metzger; Robert E Donahue; John F Tisdale
Journal:  Nat Commun       Date:  2019-10-02       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.